1
|
Lin IC, Chang CH, Chong YB, Kuo SH, Cheng YW, Lieu AS, Tseng TT, Lin CJ, Tsai HP, Kwan AL. Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma. Cells 2023; 12:2420. [PMID: 37830634 PMCID: PMC10572158 DOI: 10.3390/cells12192420] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 10/03/2023] [Accepted: 10/06/2023] [Indexed: 10/14/2023] Open
Abstract
Glioblastoma (GBM) stands as the most prevalent primary malignant brain tumor, typically resulting in a median survival period of approximately thirteen to fifteen months after undergoing surgery, chemotherapy, and radiotherapy. Nucleobindin-2 (NUCB2) is a protein involved in appetite regulation and energy homeostasis. In this study, we assessed the impact of NUCB2 expression on tumor progression and prognosis of GBM. We further evaluated the relationship between NUCB2 expression and the sensitivity to chemotherapy and radiotherapy in GBM cells. Additionally, we compared the survival of mice intracranially implanted with GBM cells. High NUCB2 expression was associated with poor prognosis in patients with GBM. Knockdown of NUCB2 reduced cell viability, migration ability, and invasion ability of GBM cells. Overexpression of NUCB2 resulted in reduced apoptosis following temozolomide treatment and increased levels of DNA damage repair proteins after radiotherapy. Furthermore, mice intracranially implanted with NUCB2 knockdown GBM cells exhibited longer survival compared to the control group. NUCB2 may serve as a prognostic biomarker for poor outcomes in patients with GBM. Additionally, NUCB2 not only contributes to tumor progression but also influences the sensitivity of GBM cells to chemotherapy and radiotherapy. Therefore, targeting NUCB2 protein expression may represent a novel therapeutic approach for the treatment of GBM.
Collapse
Affiliation(s)
- I-Cheng Lin
- Department of Surgery, Kaohsiung Municipal Siaogang Hospital, Kaohsiung 81267, Taiwan;
| | - Chih-Hui Chang
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
| | - Yoon Bin Chong
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
| | - Shih-Hsun Kuo
- Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan;
| | - Yu-Wen Cheng
- Gradate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan;
- Department of Neurosurgery, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan
| | - Ann-Shung Lieu
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
- Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan
| | - Tzu-Ting Tseng
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
| | - Chien-Ju Lin
- School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan;
| | - Hung-Pei Tsai
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
| | - Aij-Lie Kwan
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; (C.-H.C.); (Y.B.C.); (A.-S.L.); (T.-T.T.)
- Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan;
- Department of Neurosurgery, University of Virginia, Charlottesville, VA 22904, USA
| |
Collapse
|
2
|
Liang Y, Ma Y, Wang K, Xiang M, Yi B. NUCB-2/Nesfatin-1 promotes the proliferation of nasopharyngeal carcinoma cells. Cancer Cell Int 2023; 23:181. [PMID: 37635259 PMCID: PMC10463537 DOI: 10.1186/s12935-023-03038-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 08/21/2023] [Indexed: 08/29/2023] Open
Abstract
PURPOSE The association of NUCB-2/Nesfatin-1 with nasopharyngeal carcinoma (NPC) remains unclear. We clarified the role of NUCB-2/Nesfatin-1 in the development, progression and diagnosis of NPC. MATERIALS AND METHODS In nasopharyngeal carcinoma cell lines (5-8 F, 6-10B, CNE1, CNE2 and NP69), western blotting, MTT, EdU and other techniques were performed to investigate the role of NUCB-2 in nasopharyngeal carcinoma. 70 tissue samples (39 NPC and 31 rhinitis) and 140 serum samples (including NPC, rhinitis, other head and neck tumors and healthy control) were included to explore the expression of NUCB-2 and its metabolite Nesfatin-1 in tissues or serum of patients with nasopharyngeal carcinoma. RESULTS NUCB-2 level in NPC tissue was higher than that in rhinitis tissue (P < 0.05). Suppression of NUCB-2 in the NPC cell line CNE2 inhibited proliferation and clone formation of the cells; on the contrary, improvement of NUCB-2 in the NPC cell line CNE1 promoted cell propagation and clone development. An elevated serum level of NUCB-2 in NPC patients was detected, compared to that in patients with other head and neck tumors, rhinitis or healthy donors. Determination of nesfatin-1 combined with EA-IgA, VCA-IgA and Rta-IgG in serum samples for NPC diagnosis reached a sensitivity of 93.6% and a specificity of 94.5%, while the positive and negative predictive value of this diagnostic model was 89.8% and 96.6%, and the accuracy yielded 94.2%. CONCLUSION This study revealed that NUCB-2 could enhance proliferation of NPC cells and NUCB-2/nesfatin-1 has the potential to be a serological marker to aid early diagnosis of nasopharyngeal carcinoma.
Collapse
Affiliation(s)
- Yunlai Liang
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, No. 87, Xiangya Street, Kaifu District, Changsha, 410008, Hunan, China
| | - Yating Ma
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, No. 87, Xiangya Street, Kaifu District, Changsha, 410008, Hunan, China
| | - Kun Wang
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, No. 87, Xiangya Street, Kaifu District, Changsha, 410008, Hunan, China
| | - Manglin Xiang
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, No. 87, Xiangya Street, Kaifu District, Changsha, 410008, Hunan, China
| | - Bin Yi
- Department of Clinical Laboratory, Xiangya Hospital of Central South University, No. 87, Xiangya Street, Kaifu District, Changsha, 410008, Hunan, China.
| |
Collapse
|
3
|
Zhang S, Zhang T, Xu Y, Rong G, Jing J. Inhibition of NUCB2 suppresses the proliferation, migration, and invasion of rheumatoid arthritis synovial fibroblasts from patients with rheumatoid arthritis in vitro. J Orthop Surg Res 2022; 17:574. [PMID: 36585713 PMCID: PMC9801639 DOI: 10.1186/s13018-022-03453-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 12/15/2022] [Indexed: 12/31/2022] Open
Abstract
Rheumatoid arthritis (RA) is an autoimmune polyarthritis in which synovial fibroblasts (SF) play a major role in cartilage and bone destruction through tumorlike proliferation, migration, and invasion. Nesfatin-1, an 82-amino-acid-long peptide discovered by Oh-I in 2006, is derived from the precursor protein nucleobindin-2 (NUCB2). NUCB2/nesfatin-1 promotes cell proliferation, migration, and invasion in various tumors. We have previously shown that increased nesfatin-1 levels in the synovium may be associated with disease severity in patients with RA. However, the effect of NUCB2 on the tumorlike transformation of RASF has not yet been reported. The expression of NUCB2 mRNA in the synovium of RA and non-RA patients was further confirmed using three individual datasets from the NCBI GEO database. Gene set enrichment analysis (GSEA) was employed to explore the association between NUCB2 mRNA and RA-related gene signatures or signaling pathways in the GSE77298 dataset. Cell proliferation, migration, and invasion abilities were determined using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), wound healing, and transwell assays, respectively. The results showed that the levels of NUCB2 mRNA in the synovium were significantly elevated in patients with RA. Moreover, GSEA showed that high expression of NUCB2 mRNA was related to gene signatures, including those involved in the cell cycle, DNA replication, extracellular matrix-receptor interaction, and focal adhesion. Furthermore, the results of CCK-8 and EdU assays indicated that inhibition of NUCB2 markedly repressed RASF proliferation. Additionally, the results of wound healing and transwell assays demonstrated that inhibition of NUCB2 significantly suppressed the migratory and invasive abilities of RASFs. Our findings are the first to demonstrate that the inhibition of NUCB2 suppresses the proliferation, migration, and invasion of RASFs in vitro.
Collapse
Affiliation(s)
- Shuo Zhang
- Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230032, Anhui, People's Republic of China
| | - Tao Zhang
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China
| | - Yayun Xu
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China
| | - Genxiang Rong
- Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Juehua Jing
- Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230032, Anhui, People's Republic of China.
| |
Collapse
|
4
|
Ren L, Bao D, Wang L, Xu Q, Xu Y, Shi Z. Nucleobindin-2/nesfatin-1 enhances the cell proliferation, migration, invasion and epithelial-mesenchymal transition in gastric carcinoma. J Cell Mol Med 2022; 26:4986-4994. [PMID: 36065769 PMCID: PMC9549493 DOI: 10.1111/jcmm.17522] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 07/27/2022] [Accepted: 08/08/2022] [Indexed: 12/07/2022] Open
Abstract
Nesfatin-1, a newly discovered adipokine derived from nucleobindin-2 (NUCB2), has been described as a new prognostic marker in cancers. This study aimed to explore the functional role of NUCB2/nesfatin-1 in the cell proliferation, migration and invasion in gastric carcinoma (GC). The expressions of NUCB2/nesfatin-1 in GC tissues and normal adjacent tissues (NATs) were compared, and the effect of inhibition of NUCB2/nesfatin-1 on the cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in GC cell line SGC-7901 was investigated. Cell transfection was conducted to inhibit NUCB2/nesfatin-1 by short hairpin RNA. Cell proliferation, migration and invasion abilities were determined using cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), wound healing and transwell assays, respectively. The expressions of EMT markers E-Cadherin and N-Cadherin were determined using western blotting. The expression of NUCB2/nesfatin-1 protein in GC tissues was significantly increased compared with that in NATs. Consistently, the serum concentrations of NUCB2/nesfatin-1 were significantly higher in patients with GC as compared with those in the control group. Moreover, the results of CCK-8 assay and EdU assay indicated that knockdown of NUCB2/nesfatin-1 could markedly decrease SGC-7901 proliferation. Furthermore, the results of wound healing assay and transwell assay demonstrated that knockdown of NUCB2/nesfatin-1 significantly suppressed SGC-7901 migration and invasion abilities. Additionally, knockdown of NUCB2/nesfatin-1 decreased the expressions of N-Cadherin and increased the expressions of E-Cadherin in SGC-7901 cells. These findings suggest that knockdown of NUCB2/nesfatin-1 suppressed the proliferation, migration, invasion and EMT of SGC-7901 cells, suggesting a potentially promising therapeutic target for GC.
Collapse
Affiliation(s)
- Le Ren
- Department of GastroenterologySecond People's Hospital of HefeiHefeiChina
| | - Deming Bao
- Department of GastroenterologySecond People's Hospital of HefeiHefeiChina
| | - Liming Wang
- Department of GastroenterologySecond People's Hospital of HefeiHefeiChina
| | - Qin Xu
- Department of GastroenterologySecond People's Hospital of HefeiHefeiChina
| | - Yayun Xu
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of PharmacyAnhui Institute of Innovative Drugs, Anhui Medical UniversityHefeiChina
| | - Zhenwang Shi
- Department of GastroenterologySecond People's Hospital of HefeiHefeiChina
| |
Collapse
|
5
|
Expression of NUCB2/NESF-1 in Breast Cancer Cells. Int J Mol Sci 2022; 23:ijms23169177. [PMID: 36012443 PMCID: PMC9409459 DOI: 10.3390/ijms23169177] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/09/2022] [Accepted: 08/14/2022] [Indexed: 11/16/2022] Open
Abstract
Recently, the expression of NUCB2/NESF-1 has been linked to tumor development. We report NUCB2/NESF-1 expression and its relation to clinicopathological parameters in breast cancer cells. Immunohistochemical reactions were conducted on 446 cases of invasive ductal carcinoma (IDC) and 36 cases of mastopathy. The expression of NUCB2/NESF-1 was also examined at the mRNA and protein levels in breast cancer cell lines. A statistically significant higher level of NUCB2/NESF-1 in IDC cells was noted compared to that in mastopathy samples. The level of NUCB2 expression in the cytoplasm of IDC cells decreased with the increasing degree of tumor malignancy (G). Higher NUCB2 expression was found in tumors with estrogen receptor (ER)-positive and progesterone receptor (PR)-positive phenotypes compared to that in estrogen-receptor-negative and progesterone-receptor-negative cases. Moreover, a higher expression was shown in ER(+) and PR(+) MCF-7 and T47D cell lines compared to that in triple-negative MDA-MB-468 and normal human breast epithelial cells. The analysis of the five-year survival rate indicated that a positive NUCB2/NESF-1 expression in tumor cells was also associated with longer patient survival. The study results suggest that NUCB2/NESF1 may play an important role in malignant transformation and may be a positive prognostic factor in IDC.
Collapse
|
6
|
Osca-Verdegal R, Beltrán-García J, Górriz JL, Martínez Jabaloyas JM, Pallardó FV, García-Giménez JL. Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. Front Cell Dev Biol 2022; 10:879814. [PMID: 35813211 PMCID: PMC9257016 DOI: 10.3389/fcell.2022.879814] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Accepted: 05/31/2022] [Indexed: 12/12/2022] Open
Abstract
Renal cell carcinoma is the most common type of kidney cancer, representing 90% of kidney cancer diagnoses, and the deadliest urological cancer. While the incidence and mortality rates by renal cell carcinoma are higher in men compared to women, in both sexes the clinical characteristics are the same, and usually unspecific, thereby hindering and delaying the diagnostic process and increasing the metastatic potential. Regarding treatment, surgical resection remains the main therapeutic strategy. However, even after radical nephrectomy, metastasis may still occur in some patients, with most metastatic renal cell carcinomas being resistant to chemotherapy and radiotherapy. Therefore, the identification of new biomarkers to help clinicians in the early detection, and treatment of renal cell carcinoma is essential. In this review, we describe circRNAs related to renal cell carcinoma processes reported to date and propose the use of some in therapeutic strategies for renal cell carcinoma treatment.
Collapse
Affiliation(s)
- Rebeca Osca-Verdegal
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - Jesús Beltrán-García
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - José Luis Górriz
- Department of Nephrology, University Clinic Hospital, INCLIVA, University of Valencia, Valencia, Spain
| | | | - Federico V. Pallardó
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - José Luis García-Giménez
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
- Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
- INCLIVA Biomedical Research Institute, Valencia, Spain
- EpiDisease S.L. (Spin-Off CIBER-ISCIII), Parc Científic de la Universitat de València, Valencia, Spain
- *Correspondence: José Luis García-Giménez,
| |
Collapse
|
7
|
Zhou Q, Liu Y, Feng R, Zhang W. NUCB2: roles in physiology and pathology. J Physiol Biochem 2022; 78:603-617. [PMID: 35678998 DOI: 10.1007/s13105-022-00895-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2021] [Accepted: 05/10/2022] [Indexed: 11/30/2022]
Abstract
Nucleobindin2 (NUCB2) is a member of nucleobindin family which was first found in the nucleus of the hypothalamus, and had a relationship in diet and energy homeostasis. Its location in normal tissues such as stomach and islet further confirms that it plays a vital role in the regulation of physiological functions of the body. Besides, NUCB2 participates in tumorigenesis through activating various signal-pathways, more and more studies indicate that NUCB2 might impact tumor progression by promoting or inhibiting proliferation, apoptosis, autophagy, metastasis, and invasion of tumor cells. In this review, we comprehensively stated NUCB2's expression and functions, and introduced the role of NUCB2 in physiology and pathology and its mechanism. What is more, pointed out the potential direction of future research.
Collapse
Affiliation(s)
- Qing Zhou
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.,Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China
| | - Ying Liu
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.,Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China
| | - Ranran Feng
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.,Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China
| | - Wenling Zhang
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. .,Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.
| |
Collapse
|
8
|
Javadirad E, Sadeghi M, Oltulu P, Sadafi S. Associations of IL-4, IL-4R, IL-17A, and IL-17F Polymorphisms with Colorectal Cancer Risk: A Meta-Analysis, Meta-Regression, and Trial Sequential Analysis. J Interferon Cytokine Res 2022; 42:203-219. [PMID: 35576490 DOI: 10.1089/jir.2021.0204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Both interleukin (IL)-4 and IL-17 polymorphisms may be involved in the pathogenesis and progression of colorectal cancer (CRC). Herein, we designed a meta-analysis to assess the associations between IL-4, IL-4R, IL-17A, and IL-17F polymorphisms and CRC risk. Scopus, Web of Science, Cochrane Library, and PubMed databases were searched to retrieve articles published until October 21, 2021. We used crude odds ratio (OR) and 95% confidence interval assessing the association of the polymorphisms and CRC risk in 5 genetic models. Trial sequential analysis for the primary analyses was used to control random errors. Twenty-three studies (8: IL-4 rs2243250, 4: IL-4R rs1801275, 5: IL-17A rs2275913, and 6: IL-17F rs763780) were involved in the meta-analysis. The pooled OR (P-value) for the association between IL-4 rs2243250 polymorphism and the CRC risk was 1.11 (0.08), 1.27 (0.12), 1.07 (0.37), 1.09 (0.17), and 1.22 (0.12), for IL-4R rs1801275 polymorphism was 0.71 (0.18), 1.05 (0.76), 0.86 (0.37), 0.87 (0.41), and 0.69 (0.39), for IL-17A rs2275913 polymorphism was 1.83 (0.0003), 1.73 (0.06), 1.47 (<0.001), 1.61 (0.001), and 1.42 (0.15), and for IL-17F rs763780 polymorphism was 1.07 (0.48), 5.33 (0.02), 1.08 (0.49), 1.08 (0.47), and 8.42 (0.002) in allelic, homozygous, heterozygous, recessive, and dominant models, respectively. The G allele and GA genotype of IL-17A rs2275913 polymorphism and the CC genotype of IL-17F rs763780 polymorphism had an elevated risk in CRC cases. The ethnicity and genotyping method, sample size, control, and publication year were effective factors on the pooled results.
Collapse
Affiliation(s)
- Etrat Javadirad
- Department of Pathology, Clinical Research Development Center, Medical School, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Masoud Sadeghi
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Pembe Oltulu
- Pathology Department, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - Sepehr Sadafi
- Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
9
|
Smith S, Stone A, Oswalt H, Vaughan L, Ferdous F, Scott T, Dunn HW. Evaluation of early post-natal pig mammary gland development and human breast cancer gene expression. Dev Biol 2021; 481:95-103. [PMID: 34662538 DOI: 10.1016/j.ydbio.2021.10.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 10/01/2021] [Accepted: 10/11/2021] [Indexed: 12/26/2022]
Abstract
Breast cancer is the second leading cause of death in women after lung cancer, and only 5% of patients with metastatic breast cancer survive beyond ten years of diagnosis. Considering the heterogeneous subclasses of breast cancer, current cancer models have shortfalls due to copy number variants, and genetic differences of humans and immunocompromised animal models. Preclinical studies indicate stem cell activity in early post-natal mammary development may be reactivated in the human adult as a trigger to initiate cell proliferation leading to breast cancer. The goal of the work reported herein was to compare genetic expression of early development, post-natal pig mammary glands to the literature reported genes implicated in different subclasses of human breast cancer. Differentially expressed genes associated with breast cancer and present in early developing pig samples include NUCB2, ANGPTL4 and ACE. Histological staining confirmed E-cadherin, Vimentin, N-cadherin, and Claudin-1, which are all implicated in malignant cancer. Due to the homology of gene expression patterns in the developing pig mammary gland and reported genes in human breast cancer profiles, this research is worthy of further study to address a potential model using mammary development cues to unravel breast cancer biology.
Collapse
Affiliation(s)
- Shelby Smith
- School of Medicine, University of South Carolina, Columbia, SC, USA
| | - Amber Stone
- Department of Animal and Veterinary Sciences, Clemson University, Clemson, SC, USA
| | - Hannah Oswalt
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Lewis Vaughan
- University of Georgia College of Veterinary Medicine, Athens, GA, USA
| | - Farzana Ferdous
- Department of Biological Sciences, University of North Carolina, Charlotte, NC, USA
| | - Tom Scott
- Department of Animal and Veterinary Sciences, Clemson University, Clemson, SC, USA
| | - Heather W Dunn
- Department of Bioengineering, Clemson University, Clemson, SC, USA.
| |
Collapse
|
10
|
Kmiecik AM, Dzięgiel P, Podhorska-Okołów M. Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule? Int J Mol Sci 2021; 22:ijms22158313. [PMID: 34361082 PMCID: PMC8348729 DOI: 10.3390/ijms22158313] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 07/29/2021] [Accepted: 07/29/2021] [Indexed: 01/03/2023] Open
Abstract
Cancer is a heterogeneous disease, and even tumors with similar clinicopathological characteristics show different biology, behavior, and treatment responses. As a result, there is an urgent need to define new prognostic and predictive markers to make treatment options more personalized. According to the latest findings, nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) is an important factor in cancer development and progression. Nucleobindin-2 is a precursor protein of nesfatin-1. As NUCB2 and nesfatin-1 are colocalized in each tissue, their expression is often analyzed together as NUCB2. The metabolic function of NUCB2/NESF-1 is related to food intake, glucose metabolism, and the regulation of immune, cardiovascular and endocrine systems. Recently, it has been demonstrated that high expression of NUCB2/NESF-1 is associated with poor outcomes and promotes cell proliferation, migration, and invasion in, e.g., breast, colon, prostate, endometrial, thyroid, bladder cancers, or glioblastoma. Interestingly, nesfatin-1 is also considered an inhibitor of the proliferation of human adrenocortical carcinoma and ovarian epithelial carcinoma cells. These conflicting results make NUCB2/NESF-1 an interesting target of study in the context of cancer progression. The present review is the first to describe NUCB2/NESF-1 as a new prognostic and predictive marker in cancers.
Collapse
Affiliation(s)
- Alicja M. Kmiecik
- Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland;
- Correspondence: ; Tel.: +48-7-1784-1365; Fax: +48-7-1784-0082
| | - Piotr Dzięgiel
- Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland;
- Department of Physiotherapy, University School of Physical Education, 51-612 Wroclaw, Poland
| | | |
Collapse
|
11
|
Ghosh M, Sen S, Sarkar R, Maulik U. Quantum squirrel inspired algorithm for gene selection in methylation and expression data of prostate cancer. Appl Soft Comput 2021. [DOI: 10.1016/j.asoc.2021.107221] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
12
|
Skorupska A, Lenda R, Ożyhar A, Bystranowska D. The Multifaceted Nature of Nucleobindin-2 in Carcinogenesis. Int J Mol Sci 2021; 22:5687. [PMID: 34073612 PMCID: PMC8198689 DOI: 10.3390/ijms22115687] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Revised: 05/19/2021] [Accepted: 05/24/2021] [Indexed: 12/18/2022] Open
Abstract
Nucb2 is a multifunctional protein associated with a variety of biological processes. Multiple studies have revealed that Nucb2, and its derivative nesfatin-1, are involved in carcinogenesis. Interestingly, the role of Nucb2/nesfatin-1 in tumorigenesis seems to be dual-both pro-metastatic and anti-metastatic. The implication of Nucb2/nesfatin-1 in carcinogenesis seems to be tissue dependent. Herein, we review the role of Nucb2/nesfatin-1 in both carcinogenesis and the apoptosis process, and we also highlight the multifaceted nature of Nucb2/nesfatin-1.
Collapse
Affiliation(s)
| | | | | | - Dominika Bystranowska
- Department of Biochemistry, Molecular Biology and Biotechnology, Faculty of Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland; (A.S.); (R.L.); (A.O.)
| |
Collapse
|
13
|
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. Cancer Treat Res Commun 2021; 27:100336. [PMID: 33607591 DOI: 10.1016/j.ctarc.2021.100336] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 02/01/2021] [Accepted: 02/06/2021] [Indexed: 01/02/2023]
Abstract
AIM This study aims to review the current evidence regarding appetite problem in cancer patients, mainly focusing on pathophysiology, diagnosis, and treatment. INTRODUCTION Anorexia is the common symptom of malnutrition in cancer patients. Recently, the understanding of the pathophysiological mechanism of the appetite problem in cancer patients has been increasing that give impact to rigorous research to find the therapies for improving appetite in cancer patients. DISCUSSION The development of anorexia in cancer patients is a complex process that involves many cytokines, receptors, chemical mediators/substances, hormones, and peptides. Growth and differentiation factor-15 (GDF-15) and toll-like receptor (TLR-4) have recently been found to be implicated in the pathogenesis of anorexia. To help diagnose the appetite problem in cancer patients, several questionnaires can be used, starting from well-known questionnaires such as Functional Assessment of Anorexia Cachexia Therapy (FAACT), Visual Analog Scale (VAS), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ30). Several drugs with different mechanisms of action have been studied to help in improving appetite in cancer patients. New repurposed agents such as anamorelin, mirtazapine, thalidomide, and eicosapentaenoic acid (EPA) have shown a beneficial effect in improving appetite and quality of life in cancer patients, however more phase 3 clinical trial studies is still needed. CONCLUSION The pathophysiology of appetite problems in cancer patients is a complex process that involves many factors. Several drugs that target those factors have been studied, however more phase 3 clinical trial studies are needed to confirm the findings from previous studies.
Collapse
|
14
|
Tao R, Niu WB, Dou PH, Ni SB, Yu YP, Cai LC, Wang XY, Li SY, Zhang C, Luo ZG. Nucleobindin-2 enhances the epithelial-mesenchymal transition in renal cell carcinoma. Oncol Lett 2020; 19:3653-3664. [PMID: 32391090 PMCID: PMC7204623 DOI: 10.3892/ol.2020.11526] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 09/13/2019] [Indexed: 12/28/2022] Open
Abstract
Nucleobindin 2 (NUCB-2) is a multifunctional protein that contains several functional domains and is associated with a wide variety of biological processes, such as food intake and energy homeostasis. NUCB-2 has been demonstrated to be associated with worse malignant outcomes and cell migration in breast and prostate cancer. However, to the best of our knowledge, its clinical and biological significance in renal cell carcinoma remains unknown. In the present study, tissue specimens from 68 patients with renal cell carcinoma and 10 normal controls were collected for NUCB-2 mRNA and protein assays. The NUCB-2 level in the patients with renal cell cancer was significantly increased compared with the normal control patients. NUCB-2-knockout in the renal cancer cell line SK-RC-52 inhibited migration and invasion. In addition, the expression levels of molecules associated with epithelial-mesenchymal transition (EMT), including E-cadherin, β-catenin, Slug and Twist, were affected by NUCB-2 suppression and the zinc finger E-box binding to homeobox 1 (ZEB1)-dependent pathway. The AMP-dependent protein kinase (AMPK)/target of rapamycin complex (mTORC) 1 signaling pathway participates in the regulation of NUCB-2-mediated metastasis and EMT. Suppression of NUCB-2 also inhibited tumor nodule formation in a murine renal cell carcinoma tumor model. In summary, NUCB-2 increased migration, invasion and EMT in renal cell carcinoma cells through the AMPK/TORC1/ZEB1 pathway in vitro and in vivo.
Collapse
Affiliation(s)
- Ran Tao
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.,Department of Urology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China
| | - Wen-Bin Niu
- Department of Urology, Shenzhen Samii Medical Center, Shenzhen, Guangdong 518000, P.R. China
| | - Peng-Hui Dou
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154001, P.R. China
| | - Shao-Bin Ni
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Yi-Peng Yu
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Li-Cheng Cai
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Xin-Yuan Wang
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Shu-Yi Li
- Department of Pharmacy, University of California, San Diego, CA 92121, USA
| | - Cheng Zhang
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
| | - Zhen-Guo Luo
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154001, P.R. China
| |
Collapse
|
15
|
Liu QJ, Lv JX, Liu J, Zhang XB, Wang LB. Nucleobindin-2 Promotes the Growth and Invasion of Glioblastoma. Cancer Biother Radiopharm 2020; 34:581-588. [PMID: 31697592 DOI: 10.1089/cbr.2019.2829] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: Glioblastoma is one of the most malignant tumors in the brain with high mortality. In recent years, immunotherapy and targeted therapy show great prospects in the treatments for glioblastoma, whereas more effective therapeutic targets are still urgently needed to be developed. Nucleobindin-2 (NUCB2) is the precursor protein of nesfatin-1, which have a variety of metabolic functions, such as food intake and temperature regulation. In recent years, the potential link between NUCB2 and the development of multiple cancer was gradually revealed; however, the effects of NUCB2 on the progression of glioblastoma are still unclear. Methods: Immunohistochemical assays were performed to explore the NUCB2 expression levels in 94 samples of glioblastoma and corresponding nontumor tissues; patients were divided into NUCB2 high expression group and low expression group. Clinical analysis related to the clinical features, the potential link between NUCB2 expression levels, and clinical features were analyzed; the effects of NUCB2 on cell proliferation and invasion of glioblastoma were detected through colony formation and MTT assay, and transwell assay respectively. The possible effects of NUCB2 on tumor growth and metastasis were measured in mice. Results: In this study, we demonstrated that NUCB2 over-expression was correlated with the high degree of recurrence of patients with glioblastoma. Further, we also revealed that NUCB2 promoted cell proliferation and invasion of glioblastoma in vitro and promoted the growth and metastasis of glioblastoma in mice. Conclusion: This study provided evidence that NUCB2 might be a novel therapeutic target of glioblastoma.
Collapse
Affiliation(s)
- Qing-Jun Liu
- Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China
| | - Jia-Xi Lv
- Department of Neurosurgery, The Second People's Hospital of Guilin, Guilin, China
| | - Jun Liu
- Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China
| | - Xue-Bin Zhang
- Department of Pathology, Tianjin Huanhu Hospital, Tianjin, China
| | - Lei-Bo Wang
- Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China
| |
Collapse
|
16
|
Huo X, Wang H, Huo B, Wang L, Yang K, Wang J, Wang L, Wang H. FTX contributes to cell proliferation and migration in lung adenocarcinoma via targeting miR-335-5p/NUCB2 axis. Cancer Cell Int 2020; 20:89. [PMID: 32226311 PMCID: PMC7092578 DOI: 10.1186/s12935-020-1130-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 01/29/2020] [Indexed: 01/29/2023] Open
Abstract
Background Extensive studies revealed that long non-coding RNAs (lncRNAs) could act as a regulator in tumors, including lung adenocarcinoma (LUAD). LncRNA FTX transcript, XIST regulator (FTX) has been reported to regulate the biological behaviors of some cancers. Nevertheless, its functional role and molecular mechanism remain obscure in LUAD. Our current study concentrates on exploring the biological function of FTX in LUAD. Methods RT-qPCR was used to test the expression of FTX, miR-335-5p or NUCB2 in LUAD cells. The effect of FTX on LUAD progression was investigated by colony formation, EdU, flow cytometry, TUNEL, transwell and western blot assays. The interaction between microRNA-335-5p (miR-335-5p) and FTX or nucleobindin 2 (NUCB2) was confirmed by luciferase reporter assay. Results RT-qPCR showed that FTX expression was up-regulated in LUAD cell lines. Loss-of-function assay indicated that FTX accelerated cell proliferation, migration and invasion, while inhibited cell apoptosis in LUAD. Besides, miR-335-5p, lowly expressed in LUAD cells, was discovered to be sponged by FTX. Subsequently, NUCB2 was identified as a target gene of miR-335-5p. Additionally, it was confirmed that NUCB2 functioned as an oncogene in LUAD. Rescue assays indicated that LUAD progression inhibited by FTX knockdown could be restored by NUCB2 up-regulation. Conclusion FTX played an oncogenic role in LUAD and contributed to cancer development via targeting miR-335-5p/NUCB2 axis.
Collapse
Affiliation(s)
- Xiaodong Huo
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| | - Huixing Wang
- 2Pain Management Center, The Second Hospital of Tianjin Medical University, Tianjin, 300211 China
| | - Bin Huo
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| | - Lei Wang
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| | - Kuo Yang
- 3Central Laboratory/Tianjin Research Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211 China
| | - Jinhuan Wang
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| | - Lili Wang
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| | - Haitao Wang
- 1Department of Oncology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211 China
| |
Collapse
|
17
|
Calcium ions modulate the structure of the intrinsically disordered Nucleobindin-2 protein. Int J Biol Macromol 2020; 154:1091-1104. [PMID: 32184136 DOI: 10.1016/j.ijbiomac.2020.03.110] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 03/12/2020] [Accepted: 03/13/2020] [Indexed: 01/05/2023]
Abstract
Nucleobindin-2 (Nucb2) is a widely expressed multi-domain protein. Nucb2 participates in many physiological processes, i.e. calcium level maintenance, feeding regulation in the hypothalamus, emotion and stress regulation, and many others. To date, this protein has not been structurally characterized. We describe the first comparative structural analysis of two homologs, a Gallus gallus and a Homo sapiens Nucb2. The in silico analysis suggested that apo-Nucb2s contain a mosaic-like structure, consisting of intertwined disordered and ordered regions. Surprisingly, the hydrogen-deuterium exchange mass spectrometry results revealed that Nucb2 is divided into two parts: an N-terminal half with a stable mosaic-like structure and a disordered C-terminal half. However, the presence of Ca2+ induces the formation of a mosaic-like structure in the C-terminal half of the Nucb2s. The Ca2+ also affects the tertiary and quaternary structure of Nucb2s. The presence of Ca2+ leads to an overall compaction of the Nucb2 molecule, resulting in structural change that is propagated along the molecule, which in turn affects the quaternary structure of the protein. Intrinsic disorder, and the mosaic-like Ca2+ dependent structure of Nucb2s, might be seen as the molecular factors responsible for their multifunctionality. Thus, Nucb2s might function as the versatile Ca2+ sensor involved in signal transduction.
Collapse
|
18
|
Cho JM, Moon KT, Lee HJ, Shin SC, Choi JD, Kang JY, Yoo TK. Nucleobindin 2 expression is an independent prognostic factor for bladder cancer. Medicine (Baltimore) 2020; 99:e19597. [PMID: 32221080 PMCID: PMC7220399 DOI: 10.1097/md.0000000000019597] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Nucleobindin 2 (NUCB2) has been reported to play an important role in both tumorigenesis and cancer progression. This study aimed to examine the clinical significance of NUCB2 expression urothelial carcinoma of the bladder (UCB).The expression level of NUCB2 and its correlation with clinicopathological parameters was analyzed in 225 UCB tissues by immunohistochemistry. Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between NUCB2 expression and the prognosis of UCB patients. High NUCB2 expression of UCB patients significantly correlated with aggressive clinicopathological features. Patients with high NUCB2 had shorter overall survival and recurrence-free survival in Kaplan-Meier survival curve (P = .018 and P = .001, respectively).Our results show that high expression of NUCB2 associated with aggressive clinicopathological feature and predicted unfavorable prognosis in patients with UCB might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.
Collapse
Affiliation(s)
- Jeong Man Cho
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Kyong Tae Moon
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Ho Jung Lee
- Department of Pathology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Soon Cheol Shin
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Jae Duck Choi
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Jeong Yoon Kang
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| | - Tag Keun Yoo
- Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea
| |
Collapse
|
19
|
Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer. DISEASE MARKERS 2018; 2018:4272064. [PMID: 30327690 PMCID: PMC6169241 DOI: 10.1155/2018/4272064] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Revised: 07/27/2018] [Accepted: 08/05/2018] [Indexed: 12/14/2022]
Abstract
In recent researches, high expression of nesfatin-1/nucleobindin-2 (NUCB2) is linked to poor prognosis in prostate and colon cancer due to the enhancement in proliferation, migration, and invasion. However, the role of nesfatin-1 in bladder cancer is not clear. In this study, we examined the expression of NUCB2 in bladder cancer using immunohistochemistry and observed that its high expression was associated with recurrence and metastasis. In addition, the transwell assay and wound healing assay showed that cell migration and invasion were decreased with NUCB2 knockdown in T24 and 5637 cells. In vivo, tumor growth and metastasis were inhibited with shRNA treatment in T24 cells. Those results showed that NUCB2 played an important role in bladder cancer and could be considered a potent prognostic factor in bladder cancer.
Collapse
|
20
|
Xie J, Chen L, Chen W. High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer. Oncol Lett 2018; 15:9188-9194. [PMID: 29805650 PMCID: PMC5958760 DOI: 10.3892/ol.2018.8523] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 02/05/2018] [Indexed: 12/23/2022] Open
Abstract
Nucleobindin 2 (NUCB2) is mainly expressed in the hypothalamic nuclei and has a proven role in energy homeostasis. It has also been recently reported to have a key role in tumor progression. However, the clinical significance of NUCB2 in colorectal cancer (CRC) remains unknown. In the present study, the level of NUCB2 mRNA was quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in 34 paired fresh tissues from patients with CRC. RT-qPCR was followed by immunohistochemical (IHC) staining of NUCB2 protein in tissue microarrays of 251 samples to evaluate the clinical significance of NUCB2 in CRC. The RT-qPCR indicated an upregulation of NUCB2 mRNA in CRC tissues compared with normal tissues (P=0.027). IHC staining indicated a positive association between elevated NUCB2 expression and lymph node metastasis or tumor-node-metastasis (TNM) stage. Patients with CRC and lymph node metastasis demonstrated a higher expression of NUCB2 (49.5%, 50/101) compared with those without lymph node metastasis (36.7%, 55/150; P=0.043). Furthermore, NUCB2 expression was also higher in patients with CRC and TNM stage III–IV compared with those with TNM stage I–II (50.9% vs. 35.0%; P=0.011). However, Kaplan-Meier analysis indicated no significant association between NUCB2 expression and disease-free survival of patients. Additionally, multivariate analysis did not identify the upregulation of NUCB2 as an independent prognostic predictor in patients with CRC (P=0.755). In conclusion, the present study demonstrated that upregulation of NUCB2 is significantly associated with CRC metastasis, indicating that NUCB2 may be a cancer-associated oncogene associated with the aggressive progression of CRC.
Collapse
Affiliation(s)
- Jun Xie
- Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.,Department of Colorectal Surgery, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China
| | - Lina Chen
- Department of Paediatrics, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China
| | - Wenbin Chen
- Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China
| |
Collapse
|
21
|
High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. Oncotarget 2018; 8:35244-35254. [PMID: 27806328 PMCID: PMC5471050 DOI: 10.18632/oncotarget.12961] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 10/25/2016] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND This study aimed to investigate the prognostic significance of NUCB2 in clear cell renal cell carcinoma. PATIENTS AND METHODS The study retrospectively enrolled a training set (182 patients) and a validation set (434 patients) with non-metastasis (pT1-3N0M0) ccRCC from two institutional medical centers of China. NUCB2 protein expression was evaluated by immunohistochemical staining of NUCB2 antibody, and its association with clinicopathological characteristics and clinical outcomes were evaluated. The NUCB2 mRNA transcription level was evaluated through TCGA KIRC cohort (190 patients). Prognostic accuracies were evaluated by C index and Akaike information criterion. RESULTS In ccRCC tissues, NUCB2 protein expression level was positively correlated with Fuhrman grade (P = 0.002 and P < 0.001, respectively). Patients with high NUCB2 mRNA transcription level (P = 0.005) and protein expression level (P = 0.024 and P < 0.001, respectively) had shorter cancer-specific survival in Kaplan-Meier survival curve. Moreover, multivariate analysis identified NUCB2 expression level as an independent prognostic factor for cancer-specific survival. Subgroup analysis suggested that NUCB2 expression significantly stratified pT1 stage patients (P < 0.001) rather than higher pT stage patients. Therefore, a new NNF prognosis model was developed to predict the cancer-specific survival in patients with pT1N0M0 stage (C-index = 0.743). CONCLUSION NUCB2 expression level is a powerful independent prognostic factor for CSS in patients with non-metastasis (pT1-3N0M0) ccRCC.
Collapse
|
22
|
Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ, Ho YW, Kuo PL. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget 2017; 7:31336-49. [PMID: 27150059 PMCID: PMC5058760 DOI: 10.18632/oncotarget.9140] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 04/16/2016] [Indexed: 01/14/2023] Open
Abstract
Recent studies indicate that a high level of nesfatin-1/Nucleobindin-2 (NUCB-2) is associated with poor outcome and promotes cell migration in breast cancer and prostate cancer. However, the role of NUCB2 is not well known in colon cancer. In this study, NUCB-2 level in colon cancer tissue was higher than that in non-tumor tissue. Suppression of NUCB-2 in a colon cancer cell line SW620 inhibited migration and invasion. The microarray analysis showed that low expression level of transcription factor ZEB1 in NUCB-2 knockdowned SW620 cells. In addition, expression level of epithelial-mesenchymal transition (EMT)-related molecules including N-cadherin, E-cadherin, β-catenin, Slug and Twist was affected by NUCB-2 suppression and ZEB1-denepdent pathway. The signaling pathway liver kinase B1(LKB1)/AMP-dependent protein kinase (AMPK)/target of rapamycin complex (TORC) 1 was involved in regulation of NUCB-2-mediated metastasis and EMT properties. Suppression of NUCB-2 inhibited tumor nodules formation in a murine colon tumor model as well. In summary, nesfatin-1/NUCB-2 enhanced migration, invasion and EMT in colon cancer cells through LKB1/AMPK/TORC1/ZEB1 pathways in vitro and in vivo.
Collapse
Affiliation(s)
- Jung-Yu Kan
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.,Division of Gastrointestinal and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Meng-Chi Yen
- Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Jaw-Yuan Wang
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.,Division of Gastrointestinal and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.,Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Deng-Chyang Wu
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Yen-Jung Chiu
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.,Division of Gastrointestinal and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - Ya-Wen Ho
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Po-Lin Kuo
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.,Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan.,Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan
| |
Collapse
|
23
|
Xu H, Li W, Qi K, Zhou J, Gu M, Wang Z. A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma. Oncol Lett 2017; 15:2425-2430. [PMID: 29434954 DOI: 10.3892/ol.2017.7563] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Accepted: 06/15/2017] [Indexed: 11/06/2022] Open
Abstract
Previous studies have assessed nucleobindin 2 (NUCB2) expression in multiple urological cancer cell lines and detected its effect on renal cancer cell apoptosis. Additionally, certain reports have indicated a novel function of NUCB2 in promoting invasion in renal cancer. The levels of NUCB2 expression in different tumor cell lines were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Human NUCB2 and β-actin (ACTB) cDNA plasmids were inserted into lentivirus plasmids, which were then transfected into 786-O cells. Western blotting and RT-qPCR were then performed to determine the gene expression in NUCB2-knocked down cells. Apoptosis was also examined by flow cytometry subsequent to successful transfection. Finally, a transwell invasion assay was performed to investigate the effects on invasive abilities in renal cancer cells. The RT-qPCR results demonstrated a high expression of NUCB2 in 786-O, ACHN and LNCaP cells, and there was particularly high expression in renal cancer 786-O cells. Following successful transfection, downregulation of NUCB2 facilitated renal carcinoma cell apoptosis, as demonstrated by an increased apoptosis rate in the lenti-NUCB2-KD 786-O cells (13.72±0.84 vs. 3.32±0.10; lenti-NUCB2-KD group vs. negative control). Notably, a significant decreased invasion rate was observed in the NUCB2 knocked-down cells compared with negative control, suggesting an invasion-promoting effect of NUCB2. These results suggested a novel function of NUCB2 in the process of development and invasion in renal cell carcinoma. NUCB2 may be an important prognostic factor and target in the diagnosis and treatment of human renal cancer.
Collapse
Affiliation(s)
- Huan Xu
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
| | - Wenzhi Li
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.,Department of Urology, Linyi People's Hospital, Shandong University, Linyi, Shandong 276003, P.R. China
| | - Kai Qi
- Department of Surgery, Linyi People's Hospital, Shandong University, Linyi, Shandong 276003, P.R. China
| | - Juan Zhou
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
| | - Meng Gu
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
| | - Zhong Wang
- Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
| |
Collapse
|
24
|
Zeng L, Zhong J, He G, Li F, Li J, Zhou W, Liu W, Zhang Y, Huang S, Liu Z, Deng X. Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis. J Cancer 2017; 8:3062-3069. [PMID: 28928897 PMCID: PMC5604457 DOI: 10.7150/jca.19619] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Accepted: 03/17/2017] [Indexed: 12/19/2022] Open
Abstract
Metastasis is a lethal step in the progression of breast cancer. None of the metastasis-associated biomarkers identified up to now has a definite prognostic value in breast cancer patients. This study was designed to identify biomarkers for breast cancer metastasis and predictors of the prognosis of breast cancer patients. The differentially expressed proteins between 23 paired primary breast tumor and metastatic lymph nodes were identified by quantitative iTRAQ proteomic analysis. Immunohistochemistry was applied to locate and assess the expression of NUCB2 in paired primary breast tumor and metastatic lymph node tissues (n = 106). The relationship between NUCB2 expression and the clinicopathological characteristics of breast cancer patients (n = 189) were analyzed by χ2 test. Kaplan-Meier analysis and Cox hazard regression analysis were utilized to investigate the relationship between its expression and prognosis of breast cancer patients. The iTRAQ proteomic results showed that 4,837 confidential proteins were identified, 643 of which were differentially expressed in the primary breast cancer tissues and the paired metastatic lymph nodes. NUCB2 protein was found decreased in paired metastatic lymph nodes (P = 0.000), with the positive expression rate being 82% in primary breast cancer tissues and 47% in paired metastatic lymph nodes, respectively. According to Kaplan-Meier analysis, the overall survival time of patients with positive expression of NUCB2 protein were shorter than those with negative NUCB2 expression (P = 0.004). Cox regression model suggested that NUCB2 was a risk factor of breast cancer patients (P = 0.045, RR = 1.854). We conclude that NUCB2 can be used as a potential biomarker for breast cancer metastasis and a prognostic predictor of breast cancer patients.
Collapse
Affiliation(s)
- Liang Zeng
- Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China.,Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Jingmin Zhong
- Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Guangchun He
- Department of Pathology, Hunan Normal University Medical College, Changsha, Hunan 410013, China
| | - Fangjun Li
- Department of Social Medicine, Hunan Provincial People's Hospital & The Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410007, China
| | - Jing Li
- Department of Breast Internal Medicine, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Wen Zhou
- Key Laboratory of Cancer of the Ministry of Health, Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, Hunan 4100078, China
| | - Wenbin Liu
- Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Yun Zhang
- Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Sanqian Huang
- Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Zhihong Liu
- Department of Pathology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
| | - Xiyun Deng
- Department of Pathology, Hunan Normal University Medical College, Changsha, Hunan 410013, China
| |
Collapse
|
25
|
Altan B, Kaira K, Okada S, Saito T, Yamada E, Bao H, Bao P, Takahashi K, Yokobori T, Tetsunari O, Nishiyama M, Yamada M. High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer. Tumour Biol 2017; 39:1010428317703817. [PMID: 28714371 DOI: 10.1177/1010428317703817] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Nucleobindin 2 has been reported that its high expression is associated with poor outcome and promotes cell migration and lymph node metastasis in breast cancer, colon cancer, and prostate cancer. However, we aimed to investigate the nucleobindin 2 expression in gastric cancer tissues and adjacent non-tumor tissues and its potential relevance to clinicopathological factors and prognosis using immunohistochemical analysis. In our study, nucleobindin 2 level in gastric cancer tissues was higher than in non-tumor tissues. A high expression of nucleobindin 2 is significantly associated with tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, and clinical stage. Furthermore, the expression level of nucleobindin 2 protein was independent predictor of progression-free survival. In summary, nucleobindin 2 might play a crucial role in gastric cancer development and could serve as an independent predictor of prognosis of gastric cancer patients.
Collapse
Affiliation(s)
- Bolag Altan
- 1 Department of Oncology Clinical Development, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Kyoichi Kaira
- 1 Department of Oncology Clinical Development, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Shuichi Okada
- 2 Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Tsugumichi Saito
- 2 Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Eijiro Yamada
- 2 Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Halin Bao
- 3 Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Pinjie Bao
- 3 Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Kengo Takahashi
- 4 Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Takehiko Yokobori
- 5 Research Program for Omics-based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research, Maebashi, Japan
| | - Oyama Tetsunari
- 6 Department of Diagnostic Pathology, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Masahiko Nishiyama
- 7 Department of Molecular Pharmacology and Oncology, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Masanobu Yamada
- 2 Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| |
Collapse
|
26
|
Xu XM, Wang CG, Zhu YD, Chen WH, Shao SL, Jiang FN, Liao QD. Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer. Onco Targets Ther 2016; 9:4197-205. [PMID: 27471394 PMCID: PMC4948725 DOI: 10.2147/ott.s103640] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Objective Solute carrier family 39, member 14 (SLC39A14), has been identified as a potential biomarker for various cancers. However, its roles in prostate cancer (PCa) are still unclear. The aim of this study was to investigate the clinical significance of SLC39A14 in patients with PCa and its functions in malignant phenotypes of PCa cells. Patients and methods Subcellular localization and expression pattern of SLC39A14 protein were examined by immunohistochemistry. Then, the associations of SLC39A14 expression with various clinicopathological features and clinical outcome of patients with PCa were statistically evaluated. Subsequently, the effects of SLC39A14 overexpression and knockdown on PCa cell proliferation and motility were, respectively, examined by Cell Counting Kit-8, transwell, and wound-healing assays. Results The immunoreactive scores of SLC39A14 protein in human PCa tissues were significantly lower than those in normal prostate tissues. Based on the Taylor dataset, SLC39A14 downregulation occurred more frequently in patients with PCa with a higher Gleason score (P<0.001), advanced clinical stage (P=0.008), presence of metastasis (P=0.009), and prostate-specific antigen failure (P=0.006). More interestingly, the survival analysis identified SLC39A14 as an independent factor for predicting the biochemical recurrence-free survival of patients with PCa (P=0.017). Functionally, the enforced expression of SLC39A14 could suppress cell proliferation, invasion, and migration of PCa cell lines in vitro, which could be reversed by the knockdown of SLC39A14. Conclusion Decreased expression of SLC39A14 may lead to malignant phenotypes of PCa cells and aggressive tumor progression in patients with PCa. Importantly, SLC39A14 may function as a tumor suppressor and a biomarker for screening patients with biochemical recurrence following radical prostatectomy.
Collapse
Affiliation(s)
- Xiao-Ming Xu
- Xiangya Hospital, Central South University, Changsha, Hunan; Department of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang
| | | | - Yu-Di Zhu
- Department of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang
| | - Wei-Hua Chen
- Shanghai East Hospital, Tongji University, Shanghai
| | - Si-Liang Shao
- Department of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang
| | - Fu-Neng Jiang
- Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China
| | - Qian-De Liao
- Xiangya Hospital, Central South University, Changsha, Hunan
| |
Collapse
|
27
|
miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 2016; 6:6092-104. [PMID: 25714029 PMCID: PMC4467424 DOI: 10.18632/oncotarget.3341] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2014] [Accepted: 01/03/2015] [Indexed: 12/29/2022] Open
Abstract
Elucidation of the molecular targets and pathways regulated by the tumour-suppressive miRNAs can shed light on the oncogenic and metastatic processes in prostate cancer (PCa). Using miRNA profiling analysis, we find that miR-188-5p was significantly down-regulated in metastatic PCa. Down-regulation of miR-188-5p is an independent prognostic factor for poor overall and biochemical recurrence-free survival. Restoration of miR-188-5p in PCa cells (PC-3 and LNCaP) significantly suppresses proliferation, migration and invasion in vitro and inhibits tumour growth and metastasis in vivo. We also find overexpression of miR-188-5p in PC-3 cells can significantly enhance the cells' chemosensitivity to adriamycin. LAPTM4B is subsequently identified as a direct target of miR-188-5p in PCa, and is found to be significantly over-expressed in PCa. Knockdown of LAPTM4B phenotypically copies miR-188-5p-induced phenotypes, whereas ectopic expression of LAPTM4B reverses the effects of miR-188-5p. We also find that restoration of miR-188-5p can inhibit the PI3K/AKT signaling pathway via the suppression of LAPTM4B. Taken together, this is the first report unveils that miR-188-5p acts as a tumour suppressor in PCa and may therefore serve as a useful therapeutic target for the development of new anticancer therapy.
Collapse
|
28
|
Takagi K, Miki Y, Tanaka S, Hashimoto C, Watanabe M, Sasano H, Ito K, Suzuki T. Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration. Endocr J 2016; 63:287-99. [PMID: 26842712 DOI: 10.1507/endocrj.ej15-0490] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Nucleobindin 2 (NUCB2) is a multifunctional protein containing several functional domains, and associated with wide variety of biological process such as food intake and energy homeostasis. Recently, NUCB2 has been implicated in not only normal human tissues but also some kinds of human malignancies. However, its clinical and/or biological significance has largely remained unknown in endometrial carcinomas. We therefore immunolocalized NUCB2 protein in 87 endometrial carcinoma tissues and examined its clinical significance. NUCB2 immunoreactivity was detected in 19 out of 87 (22%) of endometrial carcinoma cases examined, and positively correlated with Ki67 labeling index, while there was no significant correlation between NUCB2 and stage, histological grade, and progesterone receptor status. Furthermore, NUCB2 immunoreactivity was significantly correlated with increased risk of recurrence and worse clinical outcome regardless of stage or histological grade. Subsequent multivariate analyses did reveal that NUCB2 immunoreactivity was an independent prognostic factor for both disease-free survival and endometrial cancer specific survival. In vitro experiments demonstrated that knockdown of NUCB2 using specific siRNA for NUCB2 significantly impaired cell proliferation and migration of the endometrial carcinoma cell lines, Ishikawa and Sawano cells, and that nesfatin-1 treatment significantly promoted cell proliferation and migration in Ishikawa cells. These findings possibly suggested that NUCB2 and/or nesfatin-1 had pivotal roles in the progression of endometrial carcinomas. Immunohistochemical NUCB2 status may therefore serve as a potent biomarker for endometrial carcinomas.
Collapse
Affiliation(s)
- Kiyoshi Takagi
- Departments of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Guo J, Wang M, Liu X. MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2015; 34:91. [PMID: 26338045 PMCID: PMC4559360 DOI: 10.1186/s13046-015-0209-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 08/20/2015] [Indexed: 12/20/2022]
Abstract
Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the metastatic processes in prostate cancer (PCa). We conducted microarray analyses and found that miR-195 was significantly decreased in metastatic PCa. Low miR-195 expression is an independent prognostic factor for poor biochemical recurrence-free and overall survival. Forced expression of miR-195 in PCa cells drastically inhibits proliferation, migration and invasion in vitro and inhibits tumor growth and metastasis in vivo. BCOX1 is identified as a direct target of miR-195 in PCa, and is found to be drastically increased in metastatic PCa. BCOX1 knockdown phenotypically copies miR-195-induced phenotypes, whereas forced expression of BCOX1 reverses the effects of miR-195. Collectively, this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1 upregulation might drive PCa metastasis.
Collapse
Affiliation(s)
- Jia Guo
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan, 430060, Hubei, People's Republic of China
| | - Min Wang
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan, 430060, Hubei, People's Republic of China
| | - Xiuheng Liu
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan, 430060, Hubei, People's Republic of China.
| |
Collapse
|
30
|
Ramanjaneya M, Tan BK, Rucinski M, Kawan M, Hu J, Kaur J, Patel VH, Malendowicz LK, Komarowska H, Lehnert H, Randeva HS. Nesfatin-1 inhibits proliferation and enhances apoptosis of human adrenocortical H295R cells. J Endocrinol 2015; 226:1-11. [PMID: 25869615 DOI: 10.1530/joe-14-0496] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/30/2015] [Indexed: 11/08/2022]
Abstract
NUCB2/nesfatin and its proteolytically cleaved product nesfatin-1 are recently discovered anorexigenic hypothalamic neuroproteins involved in energy homeostasis. It is expressed both centrally and in peripheral tissues, and appears to have potent metabolic actions. NUCB2/nesfatin neurons are activated in response to stress. Central nesfatin-1 administration elevates circulating ACTH and corticosterone levels. Bilateral adrenalectomy increased NUCB2/nesfatin mRNA levels in rat paraventricular nuclei. To date, studies have not assessed the effects of nesfatin-1 stimulation on human adrenocortical cells. Therefore, we investigated the expression and effects of nesfatin-1 in a human adrenocortical cell model (H295R). Our findings demonstrate that NUCB2 and nesfatin-1 are expressed in human adrenal gland and human adrenocortical cells (H295R). Stimulation with nesfatin-1 inhibits the growth of H295R cells and promotes apoptosis, potentially via the involvement of Bax, BCL-XL and BCL-2 genes as well as ERK1/2, p38 and JNK1/2 signalling cascades. This has implications for understanding the role of NUCB2/nesfatin in adrenal zonal development. NUCB2/nesfatin may also be a therapeutic target for adrenal cancer. However, further studies using in vivo models are needed to clarify these concepts.
Collapse
Affiliation(s)
- Manjunath Ramanjaneya
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Bee K Tan
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Marcin Rucinski
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Mohamed Kawan
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Jiamiao Hu
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Jaspreet Kaur
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Vanlata H Patel
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Ludwik K Malendowicz
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Hanna Komarowska
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Hendrik Lehnert
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK
| | - Harpal S Randeva
- Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland1st Medical DepartmentUniversity of Lübeck Medical School, Lübeck, GermanyDepartment of DiabetesEndocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UKAston Medical Research InstituteSchool of Life and Health Sciences, Aston University, Birmingham, UK Warwick Medical SchoolUniversity of Warwick, Coventry CV4 7AL, UKInterim Translational Research InstituteAcademic Health System, Hamad Medical Corporation, Doha, QatarDepartment of Obstetrics and GynaecologyBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Histology and EmbryologyPoznan University of Medical Sciences, Poznan, PolandDepartment of EndocrinologyMetabolism and Internal
| |
Collapse
|
31
|
Qi C, Ma H, Zhang HT, Gao JD, Xu Y. Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma. Histopathology 2014; 66:650-7. [PMID: 25322808 DOI: 10.1111/his.12587] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Accepted: 10/12/2014] [Indexed: 02/02/2023]
Abstract
AIMS Nucleobindin 2 (NUCB2) has been reported to play an important role in both tumorigenesis and cancer progression. This study aimed to examine the clinical significance of NUCB2 expression in clear cell renal cell carcinoma (ccRCC). METHODS AND RESULTS The expression level of NUCB2 and its correlation with clinicopathological parameters was analysed in 188 ccRCC tissues and adjacent non-cancerous tissues by immunohistochemistry. Samples from eight ccRCC patients were examined by Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between NUCB2 expression and the prognosis of ccRCC patients. The expression level of NUCB2 was found to be significantly higher in ccRCC tumours compared to adjacent non-cancerous tissues using immunohistochemistry, Western blotting and qRT-PCR. Moreover, high NUCB2 tumour expression was associated with high T stage and metastasis and shorter overall survival. Univariate and multivariate analysis confirmed that NUCB2 was an independent prognostic factor for overall survival. CONCLUSIONS Our results show that NUCB2 plays an important role in tumorigenesis and progression and is a potential molecular biomarker for the diagnosis and targeted therapy of ccRCC.
Collapse
Affiliation(s)
- Can Qi
- Department of Urology, the Second Hospital of Tianjin Medical University, National Key Clinical Specialty of Urology, Tianjin Key Institute of Urology, Tianjin, China
| | | | | | | | | |
Collapse
|
32
|
Duan Y, Pan C, Shi J, Chen H, Zhang S. Association between interleukin-4 gene intron 3 VNTR polymorphism and cancer risk. Cancer Cell Int 2014; 14:131. [PMID: 25484626 PMCID: PMC4258052 DOI: 10.1186/s12935-014-0131-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2014] [Accepted: 11/17/2014] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Interleukin-4(IL-4) is a critical inflammatory cytokine and has been involved in pathogenesis of cancer. To date, several studies have investigated the association between IL-4 intron 3 variable number of tandem repeats (VNTR) polymorphism and cancer risk in humans; however, the results remain controversial. We performed this meta-analysis to find a more conclusive association between this polymorphism and cancer risk. METHODS Eight eligible case-control studies were identified through searching electronic databases, including 1583 cases and 1638 controls. Odds ratio (OR) and corresponding 95% confidence interval (CI) were used to estimate the strength of the association. RESULTS The results of overall analyses indicated that the variant RP2 allele was associated with a decreased cancer risk compared with the RP1 allele (RP2/RP2 vs. RP1/RP1, OR = 0.64, 95% CI = 0.44-0.94; RP2/RP2 vs. RP1/RP1 + RP1/RP2, OR = 0.75, 95% CI = 0.60-0.92; RP2 vs. RP1, OR = 0.72, 95% CI = 0.56-0.92). In subgroup analyses stratified by ethnicity, there was evidence in the Asian population for an association between this polymorphism and cancer risk (RP2/RP2 vs. RP1/RP1 + RP1/RP2, OR = 0.79, 95% CI = 0.63-0.99; RP2 vs. RP1, OR = 0.77, 95% CI = 0.61-0.97). CONCLUSIONS IL-4 intron 3 VNTR polymorphism could influence the risk of human cancer. Due to the limitations of this meta-analysis, further well-designed and functional researches should be performed to validate our results.
Collapse
Affiliation(s)
- Yin Duan
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province PR China
| | - Chi Pan
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province PR China
| | - Jinan Shi
- Department of Medical Oncology, Zhejiang Hospital, Hangzhou, Zhejiang Province PR China
| | - Hailong Chen
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province PR China
| | - Suzhan Zhang
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province PR China
| |
Collapse
|
33
|
Lin YL, Xie PG, Wang L, Ma JG. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit 2014; 20:1376-82. [PMID: 25091018 PMCID: PMC4136940 DOI: 10.12659/msm.891247] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Background Aberrant methylation of protocadherin 17 (PCDH17) has been reported in several human cancers. However, the methylation status of PCDH17 in prostate cancer and its clinical significance remains unclear. The aim of this study was to investigate the methylation status of PCDH17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Material/Methods The methylation status of PCDH17 in 152 prostate cancer tissues and 51 non-tumoral prostate tissues was examined by methylation-specific PCR (MSP). Then the association between PCDH17 methylation and clinicopathologic parameters was analyzed. Kaplan-Meier survival analysis, log-rank test and multivariate Cox proportional hazard model analysis were used to analyze the correlation between PCDH17 methylation and prognosis of patients with prostate cancer. Results Our data demonstrated that PCDH17 methylation occurred frequently in prostate cancer. PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer. Conclusions PCDH17 methylation is a frequent tumor-specific event in prostate cancer, and is significantly correlated with shorter BCR-free survival and overall survival of patients with prostate cancer after radical prostatectomy. PCDH17 methylation in tumor samples after radical prostatectomy may be used as an independent prognostic biomarker.
Collapse
Affiliation(s)
- Ying-Li Lin
- Department of Urology, Xuzhou Cancer Hospital (Affiliated Xuzhou Hospital, Jiangsu University), Xuzhou, China (mainland)
| | - Pei-Gen Xie
- Department of Spine Surgery, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (mainland)
| | - Li Wang
- Department of Urology, Affiliated Hospital, Hebei University of Engineering, Handan, China (mainland)
| | - Jian-Guo Ma
- Department of Urology, Third Hospital, Hebei Medical University, Shijiazhuang, China (mainland)
| |
Collapse
|
34
|
Zhang H, Wang A, Qi S, Cheng S, Yao B, Xu Y. Protein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer. Int J Mol Sci 2014; 15:11665-77. [PMID: 24987951 PMCID: PMC4139806 DOI: 10.3390/ijms150711665] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2014] [Revised: 05/28/2014] [Accepted: 06/12/2014] [Indexed: 11/16/2022] Open
Abstract
Protein tyrosine kinase 7 (PTK7) has been studied in various tumors, but its role in prostate cancer remains unknown. This study is aimed to investigate the prognostic and predictive significance of PTK7 in patients with prostate cancer. PTK7 expression was evaluated by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis in 20 pairs of benign prostatic hyperplasia specimens and prostate cancer specimens. Then, we examined the immunohistochemical expression of PTK7 in 180 prostate cancer specimens and evaluated its clinical significances. Elevated PTK7 expression was significantly associated with lymph node metastases, seminal vesicle invasion, prostate cancer stage, the higher preoperative prostate-specific antigen, the higher Gleason score, angiolymphatic invasion, and biochemical recurrence. The results revealed that the overexpression of PTK7 in prostate cancer was an independent prognostic factor for poor overall survival and biochemical recurrence-free survival. The present data provide evidence that PTK7 predicts lymph node metastasis and poor overall survival and biochemical recurrence-free survival, highlighting its potential function as a therapeutic target for prostate cancer.
Collapse
Affiliation(s)
- Hongtuan Zhang
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| | - Andi Wang
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| | - Shiyong Qi
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| | - Shang Cheng
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| | - Bing Yao
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| | - Yong Xu
- Department of Urology, National Key Clinical Specialty of Urology, the Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin 300211, China.
| |
Collapse
|
35
|
Sun Z, Cui Y, Pei J, Fan Z. Association between NQO1 C609T polymorphism and prostate cancer risk. Tumour Biol 2014; 35:7993-8. [PMID: 24838947 DOI: 10.1007/s13277-014-2051-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Accepted: 05/05/2014] [Indexed: 11/25/2022] Open
Abstract
Published studies on the association between NQO1 C609T polymorphism and prostate cancer risk have yielded conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. All eligible studies of NQO1 C609T polymorphism and prostate cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manage 5.0 and Stata 11.0. A total of 6 available studies were considered in the present meta-analysis, with 717 cases and 1,794 controls. When all groups were pooled, there was no evidence that NQO1 C609T had significant association with prostate cancer under additive, recessive, dominant, and allelic models. When stratifying for the race, our analysis suggested that NQO1 C609T was associated with prostate cancer risk in Asians when using dominant (TT + CT vs CC: OR = 1.419, 95 % CI = 1.053 - 1.913, P = 0.021) and allelic models (OR = 1.337, 95 % CI = 1.014 - 1.763, P = 0.040) to analyze the data. However, no significant associations were found in Caucasians. This meta-analysis suggested that NQO1 C609T polymorphism most likely contributes to increased susceptibility to prostate cancer in the Asians. Further large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis.
Collapse
Affiliation(s)
- Zihan Sun
- Department of Laboratory Diagnosis, General Hospital of Jinan Military Region, 25 Shifan Road, Tianqiao District, Jinan, 250031, Shandong, China
| | | | | | | |
Collapse
|
36
|
Prognostic value of matrix metalloprotease-1/protease-activated receptor-1 axis in patients with prostate cancer. Med Oncol 2014; 31:968. [PMID: 24805876 DOI: 10.1007/s12032-014-0968-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Accepted: 04/17/2014] [Indexed: 12/15/2022]
Abstract
The aim of this study was to investigate the associations of matrix metalloprotease-1 (MMP-1) and its receptor protease-activated receptor-1 (PAR-1) coexpression with the clinicopathological characteristics and prognosis of patients with prostate cancer (PCa). Immunohistochemistry was performed to detect the expression changes of MMP-1 and PAR-1 proteins in 180 pairs of human PCa tissues and matched non-cancerous prostate tissues. Then, the associations of combined MMP-1 and PAR-1 expression with selected clinicopathological characteristics and patient prognosis were evaluated. Both MMP-1 and PAR-1 proteins were positively localized in cytoplasm of tumor cells in PCa tissues. Compared with non-cancerous prostate tissues, MMP-1 (PCa vs. Normal: 4.15 ± 1.28 vs. 2.37 ± 1.16, P < 0.001) and PAR-1 (PCa vs. Normal: 3.71 ± 1.21 vs. 1.55 ± 1.12, P < 0.001) protein expression were both significantly upregulated. More interestingly, the expression levels of MMP-1 in PCa tissues were positively correlated with those of PAR-1 significantly (Spearman correlation coefficient r = 0.88, P < 0.001). In addition, the coexpression of MMP-1 and PAR-1 (MMP-1-high/PAR-1-high) in PCa tissues was significantly associated with the higher Gleason score (P < 0.001), the presence of metastasis (P < 0.001) and the advanced pathological stage (P = 0.009). Furthermore, both univariate and multivariate analyses showed that MMP-1-high/PAR-1-high expression was an independent predictor for both unfavorable overall survival and biochemical recurrence-free survival. These findings confirmed for the first time that the upregulation of MMP-1 protein combined with the overexpression of PAR-1 protein may contribute to the malignant progression of PCa. More importantly, MMP-1/PAR-1 axis may be a negative prognostic factor for patients with PCa.
Collapse
|
37
|
Sun Z, Pei J, Cui F, Jing Y, Hu C. Lack of association between IL-4 -588C>T polymorphism and NHL susceptibility. Tumour Biol 2014; 35:4897-900. [DOI: 10.1007/s13277-014-1642-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 01/09/2014] [Indexed: 11/28/2022] Open
|
38
|
Expression of RABEX-5 and its clinical significance in prostate cancer. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2014; 33:31. [PMID: 24716822 PMCID: PMC3996945 DOI: 10.1186/1756-9966-33-31] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Accepted: 04/06/2014] [Indexed: 11/24/2022]
Abstract
Background While recent research has shown that expression of RABEX-5 in breast cancer and colorectal cancer has a crucial impact on tumor development, there is little information regarding RABEX-5 expression in prostate cancer. This study investigated the expression of RABEX-5 in prostate cancer by real time quantitative polymerase chain reaction and evaluated its association with clinicopathological variables, including prostate cancer patient prognosis. Methods A total of 180 patients with primary prostate cancer treated by radical prostatectomy were enrolled. Real time quantitative polymerase chain reaction was utilized to investigate mRNA expression level of RABEX-5 in 180 paired prostate cancer/adjacent non-cancerous tissues. RABEX-5 mRNA expression was divided into high expression group and low expression group and correlations between RABEX-5 mRNA and clinicopathological factors were then evaluated. Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the association between RABEX-5 mRNA expression and prognosis of patients with prostate cancer. Results Our study showed that RABEX-5 mRNA was significantly upregulated in prostate cancer tissues. The data indicated that high expression of RABEX-5 mRNA was significantly associated with lymph node metastasis (P = 0.001), clinical stage (P = 0.004), biochemical recurrence (P = 0.009), preoperative prostate-specific antigen (P < 0.001), and Gleason score (P < 0.001). High RABEX-5 mRNA expression was a significant predictor of poor biochemical recurrence free survival and overall survival both in univariate and multivariate analysis. Conclusion This is to our knowledge the first report investigating tumor RABEX-5 mRNA expression level in prostate cancer. We have shown that high RABEX-5 mRNA expression is a strong predictor of poor prognosis in prostate cancer patients treated by radical prostatectomy, and multivariate analysis confirmed RABEX-5 mRNA as an independent prognostic factor.
Collapse
|
39
|
Li P, Wang L, Liu L, Jiang H, Ma C, Hao T. Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk. Tumour Biol 2014; 35:6581-5. [PMID: 24696264 DOI: 10.1007/s13277-014-1900-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2014] [Accepted: 03/26/2014] [Indexed: 01/30/2023] Open
Abstract
In order to make a comprehensive assessment of the potential association between one genetic variant in the insulin receptor substrate 1 (IRS-1) gene, rs1801278, and colorectal cancer (CRC) risk, we conducted a meta-analysis of four epidemiological studies, which included 3,708 CRC cases and 4,176 controls. The data showed that rs1801278 polymorphism was not associated with increased CRC risk in the overall population. When stratifying by the race, the results showed that the rs1801278 polymorphism was associated with increased CRC risk under dominant model in mixed populations. Based on this meta-analysis, we conclude that the IRS-1 rs1801278 polymorphism might be a risk factor for CRC development in mixed populations. Further studies, either with larger sample size or involving other single nucleotide polymorphisms (SNPs) and haplotypes of the IRS-1 gene, are necessary to clarify the contribution of IRS-1 rs1801278 in colorectal carcinogenesis.
Collapse
Affiliation(s)
- Peng Li
- Department of Anus & Intestine Surgery, Binzhou Medical University Hospital, 661 Huangheer Road, Binzhou, 256603, Shandong, China,
| | | | | | | | | | | |
Collapse
|
40
|
Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS One 2014; 9:e91069. [PMID: 24651764 PMCID: PMC3961215 DOI: 10.1371/journal.pone.0091069] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Accepted: 02/07/2014] [Indexed: 11/19/2022] Open
Abstract
Background Lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is overexpressed in several solid malignancies. However, the expression of LAPTM4B-35 and its role in the progression of prostate cancer (PCa) is unknown. The aim of the present study was to investigate the LAPTM4B-35 expression in PCa and its potential relevance to clinicopathological variables and prognosis. Methods Immunohistochemistry was used to determine the expression of LAPTM4B-35 protein in 180 PCa tissues in comparison with 180 normal benign prostatic hyperplasia (BPH) specimens. The correlation between the expression of the LAPTM4B-35 protein and the clinicopathologic characteristics of patients with PCa was analyzed. Results Statistical analysis showed that LAPTM4B-35 expression was significantly elevated in PCa compared with the BPH controls. High LAPTM4B-35 staining was present in 71.11% of all the cases with PCa. The overexpression of LAPTM4B-35 was significantly associated with the lymph node metastasis, seminal vesicle invasion, PCa stage, higher Gleason score, higher preoperative PSA, and biochemical recurrence (BCR). The Kaplan-Meier survival analysis showed that the high expression of LAPTM4B-35 was related to the poor overall survival and BCR-free survival of patients with PCa. Multivariate Cox analysis showed that LAPTM4B-35 was an independent prognostic factor for both overall survival and BCR-free survival of patients with PCa. Conclusions Overexpression of LAPTM4B-35 may be associated with tumor progression and poor prognosis in PCa and thus may serve as a new molecular marker to predict the prognosis of PCa patients.
Collapse
|
41
|
Jia ZM, Liu Y, Cui SY. Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility. Tumour Biol 2014; 35:5527-31. [PMID: 24523023 DOI: 10.1007/s13277-014-1727-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2013] [Accepted: 02/04/2014] [Indexed: 01/15/2023] Open
Abstract
In order to make a comprehensive assessment of the potential association between one genetic variant in the cyclin-dependent kinase inhibitor 1B gene, rs2066827, and breast cancer risk, we conducted a meta-analysis of six epidemiological studies, which included 3,139 breast cancer cases and 2,936 controls. The data showed that rs2066827 polymorphism was not associated with increased breast cancer risk in overall population. When stratifying by the race, no noteworthy associations were observed in Asians or Caucasians. Based on this meta-analysis, we conclude that the cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism might not be a risk factor for breast cancer development. Further studies, either with larger sample size or involving other SNPs and haplotypes of the cyclin-dependent kinase inhibitor 1B gene, are necessary to clarify the contribution of cyclin-dependent kinase inhibitor 1B rs2066827 in breast carcinogenesis.
Collapse
Affiliation(s)
- Zhong-Ming Jia
- Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Huangheer Road, Binzhou, 256603, Shandong, China,
| | | | | |
Collapse
|
42
|
Li L, Zhang X, Xia Q, Ma H, Chen L, Hou W. Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk. Tumour Biol 2014; 35:4629-35. [PMID: 24414486 DOI: 10.1007/s13277-014-1606-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Accepted: 01/02/2014] [Indexed: 12/30/2022] Open
Abstract
Accumulating evidence has suggested that estrogen receptor alpha (ER-α) PvuII polymorphism might be involved in the development of prostate cancer (PCa). However, the results have been inconsistent. We therefore performed a meta-analysis to clarify the associations between ER-α PvuII polymorphism and PCa. A comprehensive search was conducted to identify all case-control studies of ER-α PvuII polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association and 95% confidence intervals (CIs) to give a sense of the precision of the estimate. A total of 14 studies were found to be eligible for meta-analyses of PvuII variant. Results from this study showed that ER-α PvuII polymorphism were significantly associated with PCa risk under all genetic models in overall population (homogeneous codominant model, OR = 1.57, 95% CI = 1.11-2.21, P = 0.010; heterogeneous codominant model, OR = 1.37, 95% CI = 1.06-1.77, P = 0.02; recessive model, OR = 1.27, 95% CI = 1.02-1.57, P = 0.03; dominant model, OR = 1.40, 95% CI = 1.09-1.79, P = 0.009; and allelic model, OR = 1.25, 95% CI = 1.06-1.48, P = 0.010). Further sensitivity analysis confirmed the significant association. In subgroup analyses stratified by PCa type, there was a significant association between PvuII polymorphism and sporadic PCa risk under both Caucasians and Asians. The meta-analysis indicated elected PvuII polymorphism of ER-α was a risk factor for PCa development.
Collapse
Affiliation(s)
- Liang Li
- Department of Radiology, Second Affiliated Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China
| | | | | | | | | | | |
Collapse
|
43
|
Wu H, Hu J, Liu B, Tao Y, Zhou X, Yuan X. Lack of association between interleukin-4 -524C>T polymorphism and colorectal cancer susceptibility. Tumour Biol 2013; 35:3657-62. [PMID: 24318972 DOI: 10.1007/s13277-013-1484-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 11/27/2013] [Indexed: 12/15/2022] Open
Abstract
Interleukin-4 (IL-4) -524C > T polymorphism has been implicated to alter the risk of colorectal cancer (CRC), but the results are controversial. The objective of this study was to quantitatively evaluate the association between IL-4 -524C > T polymorphism and CRC risk. A comprehensive search was conducted to identify all eligible studies of IL-4 -524C > T polymorphism and CRC risk. Statistical analysis was performed with Review Manager 5.0 and Stata 11. A total of 5 case-control studies, including 1,224 cases and 1,551 controls, were included. The combined results based on all eligible studies suggested that IL-4 -524C > T polymorphism was not associated with CRC susceptibility. When stratifying for race, the data showed that the IL-4 -524C > T polymorphism was also not associated with an increased CRC susceptibility in Caucasians. Our study suggests that IL-4 -524C > T polymorphism may be not associated with an increased CRC susceptibility.
Collapse
Affiliation(s)
- Huanlei Wu
- Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China
| | | | | | | | | | | |
Collapse
|
44
|
Cui Y, Jing Y, Sun Z. Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility. Tumour Biol 2013; 35:3385-9. [DOI: 10.1007/s13277-013-1446-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2013] [Accepted: 11/19/2013] [Indexed: 11/29/2022] Open
|
45
|
Jiang G, Xu X, Ren S, Wang L. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma. Tumour Biol 2013; 35:3405-8. [PMID: 24277379 DOI: 10.1007/s13277-013-1449-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Accepted: 11/19/2013] [Indexed: 12/29/2022] Open
Abstract
The aim of this study was to compare the effectiveness of combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) with that of RFA alone in patients with hepatocellular carcinoma (HCC). All possible trials comparing RFA plus TACE with RFA alone for HCC were included into this meta-analysis. We estimated the summary odds ratio (OR) with its 95% confidence interval (95% CI) to assess the effects. Nineteen eligible studies matched the selection criteria, including 1,728 patients. Meta-analysis showed that the combination of TACE and RFA (OR(1 year) = 2.14, 95% CI = 1.57-2.91, P < 0.001; OR(3 years) = 1.98, 95% CI = 1.28-3.07, P = 0.001; OR(5 years) = 2.70, 95% CI = 1.42-5.14, P = 0.003) were associated with higher survival rates. No evidence of publication bias was observed. High-quality evidence suggests that TACE plus RFA improve the survival rates compared with RFA alone for patients with HCC.
Collapse
Affiliation(s)
- Guisheng Jiang
- Department of Internal Neurology, Liaocheng People's Hospital, 67 Dongchangxi Road, Dongchangfu District, Liaocheng City, 252000, Shandong Province, China,
| | | | | | | |
Collapse
|
46
|
Association between interleukin-4 -590C > T polymorphism and non-Hodgkin's lymphoma risk. Tumour Biol 2013; 35:3041-5. [PMID: 24272083 DOI: 10.1007/s13277-013-1394-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2013] [Accepted: 11/05/2013] [Indexed: 10/26/2022] Open
Abstract
Many studies were performed to assess the association between IL-4 -590C > T polymorphism and non-Hodgkin's lymphoma (NHL) risk, but no consensus was available up to now. We conducted a meta-analysis to examine the association between IL-4 -590C > T polymorphism and NHL risk. We used odds ratios (ORs) to assess the strength of the association and 95% confidence intervals (CIs) to give a sense of the precision of the estimate. A total of six studies were found to be eligible for meta-analyses of IL-4 -590C > T variant. Results from this study showed that IL-4 -590C > T polymorphism was not significantly associated with NHL risk under all genetic models in overall population. Further sensitivity analysis confirmed the results. In subgroup analyses stratified by race, no significant association was found in either Caucasian or mixed populations. The meta-analysis indicated that elected -590C > T polymorphism of IL-4 may not be a risk factor for NHL development.
Collapse
|
47
|
The prognostic value of Smad4 mRNA in patients with prostate cancer. Tumour Biol 2013; 35:3333-7. [PMID: 24272204 DOI: 10.1007/s13277-013-1439-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 11/18/2013] [Indexed: 12/24/2022] Open
Abstract
The tumor suppressor gene Smad4 has been localized to chromosome 18q21.1 and is a member of the Smad family that mediates the transforming growth factor β signaling pathway suppressing epithelial cell growth. However, variable expression of Smad4 messenger RNA (mRNA) has been reported, with a loss in some cancers and increased expression in others. The aim of the present study was to investigate the Smad4 mRNA expression in prostate cancer tissues and adjacent noncancerous tissues and its potential relevance to clinicopathological variables and prognosis. The expression change of Smad4 mRNA was detected by using real-time quantitative reverse transcriptase-polymerase chain reaction analysis. The data showed that the Smad4 mRNA expression level in prostate cancer tissues was significantly lower than those in noncancerous tissues. The results indicated that the low expression of Smad4 mRNA in prostate cancer was associated with lymph node metastasis, preoperative prostate-specific antigen (PSA), and Gleason score. Kaplan-Meier survival analysis showed that patients with high Smad4 mRNA expression have longer biochemical recurrence-free survival time compared to patients with low Smad4 mRNA expression. Multivariate analysis revealed that Smad4 mRNA expression was an independent predictor of biochemical recurrence-free survival. Our results emphasize that Smad4 mRNA can be used as a predictive biomarker.
Collapse
|
48
|
Li Q, Wang Q, Xu X, Ren S, Wang L. Association between IL-4 -589C>T polymorphism and colorectal cancer risk. Tumour Biol 2013; 35:2675-9. [PMID: 24218339 DOI: 10.1007/s13277-013-1352-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2013] [Accepted: 10/23/2013] [Indexed: 01/28/2023] Open
Abstract
In order to make a comprehensive assessment of the potential association between interleukin-4 (IL-4) -589C>T and colorectal cancer (CRC) susceptibility, we conducted a meta-analysis of six epidemiological studies, which included 1,317 CRC patients and 1,659 controls. The data showed that IL-4 -589C>T was not associated with increased CRC risk in the overall population. In the subgroup analysis of IL-4 -589C>T, the results did not change when the analyses were restricted to race. Based on this meta-analysis, we conclude that IL-4 -589C>T may be not a risk factor for CRC development. Further research is needed to assess possible gene-gene or gene-environment-lifestyle interactions on CRC.
Collapse
Affiliation(s)
- Qiang Li
- Proctology Department, Liaocheng People's Hospital, Liaocheng City, 252000, Shandong Province, China,
| | | | | | | | | |
Collapse
|
49
|
Liu G, Qi C, Xu Q, Wu B, Wang Y, Xue C. Lack of association between methylenetetrahydrofolate dehydrogenase 1 G1958A polymorphism and prostate cancer risk: a meta-analysis. Tumour Biol 2013; 35:2029-33. [PMID: 24197977 DOI: 10.1007/s13277-013-1269-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 09/25/2013] [Indexed: 11/26/2022] Open
Abstract
The methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) polymorphism G1958A has been extensively investigated as a potential risk factor for prostate cancer (PCa), but the results have thus far been inconclusive. This meta-analysis was performed to derive a more precise estimation of the association. A comprehensive search was conducted to identify all case-control studies of MTHFD1 G1958A polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) give a sense of the precision of the estimate. Statistical analyses were performed using Review Manage version 5.0 and Stata 10.0. A total of six available studies were considered in the present meta-analysis, with 7,493 patients and 36,941 controls. When all groups were pooled, there was no evidence that G1958A had significant association with PCa under additive, recessive, dominant, and allelic models. This meta-analysis suggests that MTHFD1 G1958A polymorphism might not be a risk factor for PCa. However, further large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis.
Collapse
Affiliation(s)
- Guizhong Liu
- Department of Urology, Xianshuigu Hospital of Jinnan District, Tianjin, 300350, China
| | | | | | | | | | | |
Collapse
|
50
|
Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B. Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma. Tumour Biol 2013; 35:2655-9. [PMID: 24197985 DOI: 10.1007/s13277-013-1349-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2013] [Accepted: 10/22/2013] [Indexed: 12/26/2022] Open
Abstract
The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. All eligible studies were collected from the PubMed, the Cochrane Library, and the Embase electronic databases. The outcomes were overall survival rates. We used odds ratios to assess the strength of the association, and 95% confidence intervals give a sense of the precision of the estimate. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. A total of 19 available studies were considered in the present meta-analysis. When all groups were pooled, meta-analysis showed that RFA plus TACE significantly improved the survival rates of patients with HCC at 1, 3, and 5 years compared with RFA alone. The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for HCC patients.
Collapse
Affiliation(s)
- Qing-Feng Kong
- Department of Ultrasound, Jining NO.1 People's Hospital, No.6 Jiankang Road, Central District, Jining, 271011, Shandong, China
| | | | | | | | | | | |
Collapse
|